Trial
NCT04407442
Daratumumab, Azacitidine, and Dexamethasone for Treatment of Patients With Recurrent or Refractory Multiple Myeloma Previously Treated With Daratumumab
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
University of California, San Francisco
Collaborators
Janssen Pharmaceuticals; Multiple Myeloma Research Foundation
Condition
Recurrent Plasma Cell Myeloma
Intervention
Azacitidine
Why stopped
Slow enrollment and change in sponsor direction
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-04-30